Sustained-release isosorbide mononitrate as adjuvant treatment in isolated systolic hypertension in the elderly

Daniel Abad Pérez1, Iluminada García Polo2, Francisco José Rodríguez Salvanés3

  • 1Internal Medicine Department, University Hospital de Getafe, Carretera de Madrid-Toledo, Madrid, Spain. danielabadperez@hotmail.com.

Insights

Nitrate treatment did not significantly reduce pulse pressure or improve vascular function in elderly patients with isolated systolic hypertension. This study found no benefit of nitrates for this condition.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Isolated systolic hypertension is common in the elderly and linked to arterial stiffness.
  • Current antihypertensives do not address arterial stiffness, but nitrates may.
  • Nitrates' effect on arterial stiffness in elderly hypertension requires investigation.

Purpose of the Study:

  • To assess the effect of sustained-release isosorbide mononitrate on pulse pressure in elderly patients with uncontrolled isolated systolic hypertension.
  • To evaluate the impact of nitrate treatment on vascular function in this population.

Main Methods:

  • Phase III, randomized, multicenter, double-blind, placebo-controlled trial.
  • 58 patients (≥65 years) with isolated systolic hypertension received isosorbide mononitrate or placebo for 12 weeks.
  • Primary endpoint: change in clinical pulse pressure; secondary: vascular function parameters.

Main Results:

  • No significant difference in pulse pressure decline between the nitrate group (5.28 mmHg) and placebo group (7.49 mmHg).
  • No significant improvements observed in vascular function parameters or adverse events.
  • Intention-to-treat analysis showed no statistically significant benefits.

Conclusions:

  • Sustained-release isosorbide mononitrate did not demonstrate efficacy in reducing pulse pressure in elderly isolated systolic hypertension.
  • Nitrate treatment did not improve vascular function in this patient group.
  • Further research is needed to explore alternative treatments for arterial stiffness in elderly hypertension.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
650
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.6K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
70
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
319
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
977
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
72